Life Sciences 2019: Knowing where to focus
May 3, 2019Mike Sherman, former CEO of Endocyte, explains how the firm could switch gears from its in-house products to a recently acquired drug.
Mike Sherman, former CEO of Endocyte, explains how the firm could switch gears from its in-house products to a recently acquired drug.